Cited by 24Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imaging

Open access
Spires-Jones, Tara L., Calignon, Alix de, Meyer-Luehmann, Melanie, Bacskai, Brian J., Hyman, Bradley T.·2011·Methods

Abstract

Aggregation of amyloid beta peptide into senile plaques and hyperphosphorylated tau protein into neurofibrillary tangles in the brain are the pathological hallmarks of Alzheimer's disease. Despite over a century of research into these lesions, the exact relationship between pathology and neurotoxicity has yet to be fully elucidated. In order to study the formation of plaques and tangles and their effects on the brain, we have applied multiphoton in vivo imaging of transgenic mouse models of Alzheimer's disease. This technique allows longitudinal imaging of pathological aggregation of proteins and the subsequent changes in surrounding neuropil neurodegeneration and recovery after therapeutic interventions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymeth.2010.12.009

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • oAβ species accumulate at the periphery of dense-cored plaques and compact plaques enhance Aβ toxicity indirectly by creating a platform on which toxic oAβ species can accumulate or stabilize.

    “A renewed interest in the pathological role of plaques has suggested that oA␤ species accumulate at the periphery of densecored plaques (60,61) and that compact plaques enhance A␤ toxicity indirectly by creating a platform on which toxic oA␤ species can accumulate or stabilize.”

    From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [61]

    The Discussion (page unavailable) links plaques to nearby neuronal damage and identifies soluble Aβ as a possible mediator. It does not say that oligomeric Aβ accumulates at the periphery of dense-cored plaques or that compact plaques provide a platform that stabilizes it. Searches for oligomers at plaque edges and for the proposed platform mechanism found no passage addressing those points. (LLM, conf=0.70)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 14

  1. [2]Gomez-Isla T Spires T de Calignon A Hyman BT Aminoff MJ Boller F Swaab DF 2008 Handbook of clinical Neurology 89 Elsevier Edinburgh
  2. [4]Gomez-Isla T Hollister R West H Mui S Growdon JH Petersen RC Parisi JE Hyman BT 1997 Ann Neurol 41 17 24 9005861
  3. [9]Meyer-Luehmann M Spires-Jones TL Prada C Garcia-Alloza M de Calignon A Rozkalne A Koenigsknecht-Talboo J Holtzman DM Bacskai BJ Hyman BT 2008 Nature 451 720 4 18256671 PMC3264491
  4. [20]Spires TL Meyer-Luehmann M Stern EA McLean PJ Skoch J Nguyen PT Bacskai BJ Hyman BT 2005 J Neurosci 25 7278 87 16079410 PMC1820616
  5. [26]Spires-Jones TL de Calignon A Matsui T Zehr C Pitstick R Wu HY Osetek JD Jones PB Bacskai BJ Feany MB Carlson GA Ashe KH Lewis J Hyman BT 2008 J Neurosci 28 862 7 18216194 PMC6670992
  6. [27]Spires-Jones TL Mielke ML Rozkalne A Meyer-Luehmann M de Calignon A Bacskai BJ Schenk D Hyman BT 2009 Neurobiol Dis 33 213 20 19028582 PMC2672591
  7. [33]Spires-Jones TL Meyer-Luehmann M Osetek JD Jones PB Stern EA Bacskai BJ Hyman BT 2007 Am J Pathol 171 1304 11 17717139 PMC1988879
  8. [34]Garcia-Alloza M Dodwell SA Meyer-Luehmann M Hyman BT Bacskai BJ 2006 J Neuropathol Exp Neurol 65 1082 9 17086105
  9. [37]Garcia-Alloza M Borrelli LA Rozkalne A Hyman BT Bacskai BJ 2007 J Neurochem 102 1095 104 17472706
  10. [38]Garcia-Alloza M Prada C Lattarulo C Fine S Borrelli LA Betensky R Greenberg SM Frosch MP Bacskai BJ 2009 J Neurochem 109 1636 47 19457117 PMC3281746
  11. [39]Meyer-Luehmann M Mielke M Spires-Jones TL Stoothoff W Jones P Bacskai BJ Hyman BT 2009 J Neurosci 29 12636 40 19812338 PMC2789808
  12. [40]Spires TL Orne JD SantaCruz K Pitstick R Carlson GA Ashe KH Hyman BT 2006 Am J Pathol 168 1598 607 16651626 PMC1606598
  13. [45]Spires-Jones TL Meyer-Luehmann M Osetek JD Jones PB Stern EA Bacskai BJ Hyman BT 2007 Am J Pathol 171 1304 11 17717139 PMC1988879
  14. [46]D’Amore JD Kajdasz ST McLellan ME Bacskai BJ Stern EA Hyman BT 2003 J Neuropathol Exp Neurol 62 137 45 12578223

Cited by

Sorted by citations

Authors
Spires-Jones, T. L., Calignon, A. D., Meyer-Luehmann, M., Bacskai, B. J., & Hyman, B. T.
Affiliations
Harvard University (US)
Venue
Methods
Publisher
Elsevier BV
Published
2011-03
Volume
53
Issue
3
Pages
201-207
ISSN
1046-2023 (ISSN-L)
OpenAlex
W2092395722
Cited by
24
References
44
Citations by year
2024: 1 · 2023: 1 · 2022: 2 · 2020: 2 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 3
FWCI
2.38
Type
journal article
Language
en
Open access
Locations
  • Methods (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
NIH (AG08487, K99AG33670, EB000768, AG026249)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, amyloid-beta aggregation, amyloid plaques, tau hyperphosphorylation, neurofibrillary tangles, neurodegeneration, in vivo imaging, multiphoton microscopy, transgenic mouse model, longitudinal imaging
MeSH terms
Alzheimer Disease, Amyloid, Anesthesia, Animals, Brain, Craniotomy, Disease Models, Animal, Genetic Vectors, Humans, Image Processing, Computer-Assisted, Neurofibrillary Tangles, Microscopy, Fluorescence, Multiphoton, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review